Find out about new COVID-19 treatments for people with MS.
The government announced on 8 December 2021 that people with MS in the UK would be eligible for one of two new treatments if they catch COVID-19 - molnupiravir and Ronapreve. Since then, another treatment has been recommended by the NHS - sotrovimab.
Until now, COVID-19 treatments have only been available for people already in hospital. These new treatments are for people soon after catching COVID-19.
We have several vaccines doing an incredible job protecting people from COVID-19. But we can’t rely on vaccines alone because they’re not 100% effective. We also need treatments to stop people getting seriously ill if they catch COVID-19.
What are the new COVID-19 treatments?
The three new COVID-19 treatments are called molnupiravir, sotrovimab and Ronapreve. They work in different ways.
Molnupiravir (brand name Lagevrio)
- Molnupiravir is an antiviral treatment. Viruses work by making lots of copies of themselves inside your body. An antiviral treatment targets the virus at an early stage, making it harder for it to make copies of itself. This lowers the level of virus circulating in your body.
- Another antiviral treatment already available is remdesivir. This is available for people hospitalised with COVID-19, but only on a very limited basis.
Sotrovimab (brand name Xevudy)
- Sotrovimab is an antibody treatment. Antibodies are molecules that our immune system makes. The antibodies recognise and neutralise threats.
- The antibodies in sotrovimab target the virus. They attach themselves to the virus and stop it from infecting our cells.
- If you’re offered sotrovimab, it’ll be given through a drip in your arm (an infusion). That would usually be at your local hospital or in a local health centre.
Ronapreve (drug names casirivimab and imdevimab)
- Ronapreve is, like sotrovimab, an antibody treatment.
- It’s given through a drip into the arm (an infusion). That would usually be at your local hospital or in a local health centre.
Other antibody treatments for COVID-19
Other antibody treatments are being used to treat people in hospital with COVID-19. This includes tocilizumab, the arthritis treatment. Dexamethasone (a steroid) is also being used to treat COVID-19.
These treatments target the immune system itself. This might seem counter-intuitive when fighting a virus. But some severe complications from COVID-19 happen because the immune system overreacts.
Why are people with multiple sclerosis eligible for these treatments?
MS is listed as one of the conditions making people eligible for direct access to the treatments. This is great news. It will hopefully prevent people with MS from being hospitalised with serious illness. But we know it can feel scary to be included in a group described as “the most vulnerable”. Especially as most people with MS haven’t been considered as “clinically extremely vulnerable” during the pandemic.
The decision isn’t based on any new information showing that MS can make people more vulnerable to getting seriously ill with COVID-19. And being eligible for these treatments doesn’t mean the vaccines haven’t been effective for you.
But we know some people with MS are at greater risk of severe illness if they catch COVID-19. This is because they have other risk factors. And some DMTs can make it less likely the vaccine will be as effective for you.
The Association of British Neurologists and our medical advisers recommend everyone with MS to get vaccinated. This includes the booster, when offered. Getting vaccinated is still the best way for most people to protect themselves and others. And people with MS can already book a booster jab three months after their primary doses.
How do I get molnupiravir, sotrovimab or Ronapreve?
You can now find the latest on how to get molnupiravir, sotrovimab or Ronapreve on our 'MS and coronavirus care and support' page.
The UK government announced in December 2021 that if you’ve got MS, the NHS should contact you to let you know you are eligible for one of these treatments if you test positive. That should still happen in England, though you might not be contacted in advance if you’re in Wales, Scotland or Northern Ireland.
The NHS might send a letter, email or text with this information. You might need to check your email spam filter in case it's got stuck there.
If you've been diagnosed more recently than 15 November this year, your diagnosis won't be on the national system. In England, your neurologist will get in touch in the coming weeks instead. You don't need to contact them.
You might have already received a PCR testing kit to keep at home, with a letter explaining what to do if you notice symptoms. If you haven't, and you get symptoms, you can order a PCR test as you normally would. In Scotland, if you can't get to a testing site, you can order one to keep at home in case you get symptoms. In England, if you haven't received a PCR testing kit by 10 January, call 119 for advice (choose the 'test and trace' option).
If your PCR test result is positive, you should hear from the NHS in England, Northern Ireland or Wales within 24 hours to discuss your treatment options. If you haven't heard by then, call your GP or 111 who can refer you. In Scotland, if you get a positive PCR result, find your local health board's COVID team and call them to arrange an assessment.
Molnupiravir is taken as a tablet. So someone can collect it for you or you can have it delivered to your home.
Sotrovimab and Ronapreve are given as an infusion at a clinic. When the NHS contact you to discuss your treatment option, they should also discuss how you can get safely to and from the clinic.
These new treatments should be available across England, Wales and Northern Ireland from 16 December, and in Scotland from 22 December.
If you have any difficulty accessing these treatments, please get in touch with us so that we can raise the kinds of issues people are having with the NHS.
The PANORAMIC research study into molnupiravir
A study called PANORAMIC is also looking at molnupiravir. PANORAMIC is a platform trial like our own Octopus trial. So it’ll test several treatments over time.
They’re recruiting 10,000 people to take part, and anyone over 50 is eligible. Including adults with health conditions like MS or people receiving treatments making them more vulnerable.
If your PCR test is positive and you’re eligible for molnupiravir, you can sign up for the study on their website. The research team might also get in touch through your GP.
If you agree to be part of the trial, you'll be randomly assigned to take molnupiravir or continue with the usual care.
The first results are expected in early 2022. And they’ll help the NHS develop a plan to offer the treatment on a wider scale.